Enanta Pharmaceuticals, Inc.

ENTA

$14.13

+0.78%

2026-09-04 11:52:33 EDT+$0.11

Healthcare

Biotechnology

NASDAQ

Active Trading

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral ...

Key Metrics of ENTA

Snapshot

Latest / TTM · 6 periods

Market Cap

$407.68M

ROCE

-24.2%

EV / EBITDA

-9.25x

+12.6% YoY

FCF Yield

-9.1%

+3.5% YoY

Cash Conversion Cycle

-957.6d

Current Ratio

3.76

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$1.15B	$1.07B	$234.22M	$219.19M	$255.39M	$407.68M
Enterprise ValueCompany value including debt and cash adjustments.	$1.10B	$1.05B	$175.35M	$408.01M	$424.15M	$429.92M
EV / SalesHow many dollars investors pay per dollar of sales.	11.29x	12.20x	2.21x	6.03x	6.49x	6.59x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-10.51x	-8.82x	-1.42x	-3.90x	-5.99x	-9.25x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.48	0.15	0.48	-1.81	-2.38	-0.48

Returns + ROCE gauge

ROCE latest

-24.2%

Prev year -36.8%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-19.8%	-37.9%	-61.7%	-90.1%	-126.5%	-61.8%
ROAProfit generated from total assets.	-17.9%	-32.0%	-28.9%	-30.8%	-29.2%	-21.3%
ROICReturn generated on invested operating capital.	-26.9%	-39.1%	-32.6%	-33.3%	-32.5%	-23.2%
ROCEOperating return on long-term capital used.	-27.1%	-35.3%	-34.3%	-38.1%	-36.8%	-24.2%
Earnings YieldEarnings as a percentage of market value.	-6.9%	-11.4%	-57.1%	-52.9%	-32.1%	-15.5%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-70.75M	$-86.91M	$-106.95M	$-85.93M	$-24.64M	$-24.00M
FCFECash flow available to equity holders after debt flows.	$-70.75M	$-86.91M	$87.46M	$-124.19M	$-58.65M	$-69.28M
FCF YieldFree cash flow divided by market capitalization.	-6.2%	-8.1%	-47.9%	-44.1%	-12.6%	-9.1%
Income QualityHow well accounting earnings are backed by cash flow.	0.89	0.70	0.77	0.68	0.24	0.56
Capex / OCFShare of operating cash flow spent on capital expenditures.	-1.1%	-2.5%	-8.8%	-22.8%	-66.9%	-4.6%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	228.7d	207.7d	182.6d	208.6d	38.5d	36.5d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	0.0d	155.0d	994.2d
Operating CycleTime from buying inventory to collecting receivables.	228.7d	207.7d	182.6d	208.6d	38.5d	36.5d
Cash Conversion CycleNet days cash is tied in operations.	228.7d	207.7d	182.6d	208.6d	-116.6d	-957.6d

Snapshot

Latest / TTM: —

Market Cap

$407.68M

ROE

-61.8%

FCF Yield

-9.1%

Current Ratio

3.76

Upstream

AbbVie Inc.NYSE:ABBV Thermo Fisher Scientific Inc. (Patheon CDMO)NYSE:TMOUnnamed CDMOs (Clinical-Stage Drug Substance & Drug Product Manufacturers)Unnamed CROs (Clinical Research Organizations)Laboratory Reagent & Equipment Suppliers (Thermo Fisher, MilliporeSigma, Agilent, etc.)Unnamed APCIs / Fine Chemical SuppliersUnnamed Excipient & Packaging Suppliers

Downstream

AbbVie Inc.NYSE:ABBVOMERS Life Sciences (OMERS Capital Partners)National Institute of Allergy and Infectious Diseases (NIAID)Shionogi & Co., Ltd.TSE:4507Novartis AGNYSE:NVS

Proxies

Royalty Pharma plcNASDAQ:RPRX Atea Pharmaceuticals, Inc.NASDAQ:AVIR BioCryst Pharmaceuticals, Inc.NASDAQ:BCRX Arvinas, Inc.NASDAQ:ARVN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Enanta Pharmaceuticals, Inc.

Key Metrics of ENTA

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of ENTA

Upstream

Downstream

Proxies

Key Metrics of ENTA

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of ENTA

Upstream

Downstream

Proxies